Ainos, Inc. Announces Global Exclusive License of VELDONA to BioPhoenix

What Happened

• Ainos, Inc. (AIMD) announced on September 28, 2026 (agreement dated September 24, 2026) that it entered a Global Exclusive License Agreement with BioPhoenix Co., Ltd. (Taiwan) for Ainos’s VELDONA® low‑dose oral interferon alpha technology. The license is exclusive, worldwide, transferable and sublicensable for the Licensed Indications: Sjögren’s Disease and Thrombocytopenia.
• In consideration, BioPhoenix will pay Ainos a $600,000 upfront license fee (payable after delivery of a complete data package and written confirmation of technology transfer) and a one‑time fee when BioPhoenix grants its first sublicense. If BioPhoenix licenses all additional specified indications, total license fees (upfront plus first sublicense fee) would be approximately $10.0 million. Ainos will also receive 25% of BioPhoenix’s net sublicensing revenue for the Licensed Indications.

Key Details

• Agreement date: September 24, 2026; 8-K filed September 28, 2026.
• Licensed indications: Sjögren’s Disease and Thrombocytopenia; territory: worldwide; exclusivity is irrevocable and sublicensable.
• Payment/royalty terms: $600,000 upfront; one‑time first‑sublicense fee; ~ $10M total possible license fees if all additional indications are licensed; 25% of net sublicensing revenue.
• Term and limits: license runs on an indication‑by‑indication and country‑by‑country basis until the later of the last‑to‑expire patent covering the indication or 20 years after the Effective Date; Ainos may not compete with the Licensed Indications during the term and for 10 years after termination. Agreement includes ROFR and call option for certain Phase 2‑progressed indications and options to license other indications under separate agreements; termination allowed for uncured material breach or insolvency.

Why It Matters

• This deal monetizes Ainos’s VELDONA® platform via a global commercial partner, providing near‑term cash ($600K upfront) and the potential for additional milestone/sublicense payments and ongoing revenue (25% of net sublicensing proceeds).
• The exclusive worldwide rights and non‑compete limit Ainos’s ability to commercialize these specific indications directly, shifting future development and commercialization responsibilities (and costs) toward BioPhoenix while preserving upside via sublicensing revenue.
• Investors should note the agreement’s patent/term structure, payment triggers (data package and tech transfer confirmation), and the potential ~$10M cap on certain license fees disclosed in the filing. Ainos also furnished a related press release as Exhibit 99.1 to the 8‑K.